Ad
related to: double therapy for copdReview Common COPD Symptoms & Talk To Your Doctor If You Are Experiencing Them. Diagnosed With COPD? Learn More About The Causes & Risk Factors Of Your Condition.
- Life With COPD
Hear From A Real Patient About
Their Journey With COPD.
- COPD Inhaler Medication
Learn How This Inhaler Option Works
To Help Reduce Flare-Ups.
- Doctor Discussion Guide
Download The Guide To Help Make
Talking To Your Doctor Easier.
- Life With COPD
Search results
People also ask
Is there a bias between triple therapy and dual therapy in COPD?
What is triple inhaled therapy for chronic obstructive pulmonary disease (COPD)?
Does triple therapy improve obstructive pulmonary disease (COPD) mortality?
Jan 14, 2022 · A recent network meta-analysis aimed to directly compare triple ICS/LABA/LAMA with corresponding either dual LABA/LAMA or ICS/LABA therapies administered as FDC via the same inhaler device has provided important information on the possible positioning of triple therapy FDC in the treatment of COPD. 29 It included ETHOS (Efficacy and Safety of ...
Apr 18, 2018 · The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA ...
- David A. Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard J. Criner, Nicola C. Day, Mark...
- 2018
Jul 5, 2021 · Most double-blind, international multicenter, randomized controlled trials of triple therapy have shown to lead to a lower risk of COPD exacerbation, a greater reduction in symptoms, a slower disease progression, better lung function and a promising signal of reduced all-cause mortality than dual therapies as shown in Supplementary Table 1.
- Yong-Hua Gao, Rong-Chang Chen
- 2021
Jun 24, 2020 · Triple therapy with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) was shown to lead to a lower risk of COPD exacerbations, a...
- Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, R...
- 2020
- Search Strategy
- Study Selection and Data Extraction
- Quality Score and risk-of-bias Assessment
- Data Synthesis and Statistical Analysis
This meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement . This study was prospectively registered in Prospero (CRD42020186726). We used the following search terms in the PubMed, MEDLINE (OvidSP), EMBASE and Cochrane Library databases to identify studies published up to ...
Data were independently extracted by two reviewers. Any difference in opinion about eligibility was resolved through consensus. We collected information from each randomized trial about study features (title, year, author, study design and duration of follow-up, etc.), participants (mean age, sex, current smoker, etc.), interventions (control thera...
Cochrane's Collaboration tool was used to assess the quality of each randomized trial and the risk of bias. We analysed included trials for allocation concealment, random sequence generation, blinding of the outcome assessment, incomplete outcome data, selective reporting, blinding of the participants and personnel, and other biases.
We used RevMan 5.3 software for all statistical analyses. The degree of heterogeneity among RCTs was evaluated with the Q test and I2 statistic. I2values ≥ 50% were considered to represent significant heterogeneity, in which case a random-effects model was applied. We combined continuous data using the inverse-variance test for the risk ratio, haza...
- Huanyu Long, Hongxuan Xu, Jean-Paul Janssens, Yanfei Guo
- 2021
Aug 28, 2023 · Currently, the triple therapies available in a single inhaler device are: fluticasone furoate/vilanterol/umeclidinium for once daily administration (OD), beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide for twice a day administration (BID), and budesonide/glycopyrronium bromide/formoterol fumarate (BGF) for BID administrati...
Sep 21, 2021 · Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization.
